KRAS-Mutant Non-Small Cell Lung Cancer: An Emerging Promisingly Treatable Subgroup
نویسندگان
چکیده
منابع مشابه
Cancer Therapy: Preclinical Efficacy of BET Bromodomain Inhibition in Kras-Mutant Non–Small Cell Lung Cancer
Purpose: Amplification of MYC is one of the most common genetic alterations in lung cancer, contributing to a myriad of phenotypes associated with growth, invasion, and drug resistance. Murine genetics has established both the centrality of somatic alterations of Kras in lung cancer, as well as the dependency ofmutantKras tumors onMYC function.Unfortunately, drug-like small-molecule inhibitors ...
متن کاملTargeting KRAS-mutant non-small cell lung cancer with the Hsp90 inhibitor ganetespib.
Mutant KRAS is a feature of more than 25% of non-small cell lung cancers (NSCLC) and represents one of the most prevalent oncogenic drivers in this disease. NSCLC tumors with oncogenic KRAS respond poorly to current therapies, necessitating the pursuit of new treatment strategies. Targeted inhibition of the molecular chaperone Hsp90 results in the coordinated blockade of multiple oncogenic sign...
متن کاملEfficacy of BET bromodomain inhibition in Kras-mutant non-small cell lung cancer.
PURPOSE Amplification of MYC is one of the most common genetic alterations in lung cancer, contributing to a myriad of phenotypes associated with growth, invasion, and drug resistance. Murine genetics has established both the centrality of somatic alterations of Kras in lung cancer, as well as the dependency of mutant Kras tumors on MYC function. Unfortunately, drug-like small-molecule inhibito...
متن کاملA RAS renaissance: emerging targeted therapies for KRAS-mutated non-small cell lung cancer.
Of the numerous oncogenes implicated in human cancer, the most common and perhaps the most elusive to target pharmacologically is RAS. Since the discovery of RAS in the 1960s, numerous studies have elucidated the mechanism of activity, regulation, and intracellular trafficking of the RAS gene products, and of its regulatory pathways. These pathways yielded druggable targets, such as farnesyltra...
متن کاملRealities of KRAS-mutated non-small cell lung cancer
Correspondence to Young Joo Min, M.D. Division of Oncology, Department of Hematology and Oncology, Ulsan University Hospital, 877 Bangeojinsunhwan-doro, Dong-gu, Ulsan 44033, Korea Tel: +82-52-250-8832 Fax: +82-52-251-8009 E-mail: [email protected] The most common histologic subtype of non-small cell lung cancer is adenocarcinoma. Adenocarcinoma has targetable gene alterations such as epidermal...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Frontiers in Oncology
سال: 2021
ISSN: 2234-943X
DOI: 10.3389/fonc.2021.672612